{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:41:13Z","timestamp":1790642473721,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The relationship between anti-estrogen drugs and macular telangiectasia type 2 (MacTel-2) remains unknown. Here we report a case with anti-estrogen maculopathy resembling MacTel-2 with improved visual function and macular morphology following cessation of anti-estrogen drugs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 53-year-old woman presented with a 5-month history of central vision loss and anorthopia in both eyes. She had received oral tamoxifen followed by toremifene for 69\u2009months. Funduscopy, fluorescein angiography, and optical coherence tomography (OCT) revealed MacTel-2-like findings OU. Fundus autofluorescence (FAF) showed hyper-autofluorescence at the fovea OU. Visual acuity, macular morphology on OCT, and FAF findings gradually improved after cessation of anti-estrogen drugs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In the present case, visual acuity, macular morphology, and impairment of the retinal pigment epithelium (RPE) improved following cessation of anti-estrogen drugs, suggesting the relationship between retinal toxicity of anti-estrogen drugs and the development of MacTel-2-like findings. From these results and the previous observations, toxicity of both photoreceptor and RPE cells caused by anti-estrogen drugs may contribute to the development of anti-estrogen maculopathy similar to MacTel-2.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12886-019-1280-1","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T13:02:39Z","timestamp":1577710959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis"],"prefix":"10.1186","volume":"19","author":[{"given":"Akihiro","family":"Shinkai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8181-6252","authenticated-orcid":false,"given":"Wataru","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"1280_CR1","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1200\/JCO.1996.14.3.1018","volume":"14","author":"SG Nayfield","year":"1996","unstructured":"Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. Rev J Clin Oncol. 1996;14:1018\u201326.","journal-title":"Rev J Clin Oncol"},{"issue":"Pt 3","key":"1280_CR2","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/eye.1997.64","volume":"11","author":"R Tang","year":"1997","unstructured":"Tang R, Shields J, Schiffman J, Li H, Locher D, Hampton J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye (Lond). 1997;11(Pt 3):295\u20137.","journal-title":"Eye (Lond)"},{"key":"1280_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1034\/j.1600-0420.2003.00116.x","volume":"81","author":"M Parkkari","year":"2003","unstructured":"Parkkari M, Paakkala AM, Salminen L, Holli K, Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand. 2003;81:495\u20139.","journal-title":"Acta Ophthalmol Scand"},{"key":"1280_CR4","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/archophthalmol.2011.2741","volume":"130","author":"E Rahimy","year":"2012","unstructured":"Rahimy E, Sarraf D. Bevacizumab therapy for tamoxifen-induced crystalline retinopathy and severe cystoid macular edema. Arch Ophthalmol. 2012;130:931\u20132.","journal-title":"Arch Ophthalmol"},{"key":"1280_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000479932","volume":"60","author":"UEK Wolf-Schnurrbusch","year":"2018","unstructured":"Wolf-Schnurrbusch UEK, Leung I, Sallo FB, Clemons TE, Chew EY, Bird AC, MacTel Study Group, et al. Potential effects of hormone therapy in type 2 idiopathic macular telangiectasia. Ophthalmic Res. 2018;60:38\u201342.","journal-title":"Ophthalmic Res"},{"key":"1280_CR6","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.ajo.2014.02.046","volume":"157","author":"RR Doshi","year":"2014","unstructured":"Doshi RR, Fortun JA, Kim BT, Dubovy SR, Rosenfeld PJ. Pseudocystic foveal cavitation in tamoxifen retinopathy. Am J Ophthalmol. 2014;157:1291\u20138.e3.","journal-title":"Am J Ophthalmol"},{"key":"1280_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000485739","volume":"9","author":"A Behrens","year":"2018","unstructured":"Behrens A, Sallam A, Pemberton J, Uwaydat S. Tamoxifen use in a patient with idiopathic macular telangiectasia type 2. Case Rep Ophthalmol. 2018;9:54\u201360.","journal-title":"Case Rep Ophthalmol"},{"key":"1280_CR8","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/j.ophtha.2010.04.001","volume":"117","author":"MB Powner","year":"2010","unstructured":"Powner MB, Gillies MC, Tretiach M, Scott A, Guymer RH, Hageman GS, et al. Perifoveal muller cell depletion in a case of macular telangiectasia type 2. Ophthalmology. 2010;117:2407\u201316.","journal-title":"Ophthalmology"},{"key":"1280_CR9","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1136\/bjo.2007.131409","volume":"92","author":"I Maruko","year":"2008","unstructured":"Maruko I, Iida T, Sekiryu T, Fujiwara T. Early morphological changes and functional abnormalities in group 2A idiopathic juxtafoveolar retinal telangiectasis using spectral domain optical coherence tomography and microperimetry. Br J Ophthalmol. 2008;92:1488\u201391.","journal-title":"Br J Ophthalmol"},{"key":"1280_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/IAE.0000000000000863","volume":"36","author":"P Charbel Issa","year":"2016","unstructured":"Charbel Issa P, Heeren TF, Kupitz EH, Holz FG, Berendschot TT. Very early disease manifestations of macular telangiectasia type 2. Retina. 2016;36:524\u201334.","journal-title":"Retina"},{"key":"1280_CR11","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1056\/NEJMoa1815111","volume":"381","author":"ML Gantner","year":"2019","unstructured":"Gantner ML, Eade K, Wallace M, Handzlik MK, Fallon R, Trombley J, et al. Serine and lipid metabolism in macular disease and peripheral neuropathy. N Engl J Med. 2019;381:1422\u201333.","journal-title":"N Engl J Med"},{"key":"1280_CR12","first-page":"1134","volume":"2015","author":"SA Morad","year":"1851","unstructured":"Morad SA, Cabot MC. Tamoxifen regulation of sphingolipid metabolism--therapeutic implications. Biochim Biophys Acta. 1851;2015:1134\u201345.","journal-title":"Biochim Biophys Acta"},{"key":"1280_CR13","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ajo.2009.04.030","volume":"148","author":"WT Wong","year":"2009","unstructured":"Wong WT, Forooghian F, Majumdar Z, Bonner RF, Conningham D, Chew EY. Fundus autofluorescence in type 2 idiopathic macular telangiectasia: correlation with optical coherence tomography and microperimetry. Am J Ophthalmol. 2009;148:573\u201383.","journal-title":"Am J Ophthalmol"},{"key":"1280_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1034\/j.1600-0773.2001.088001027.x","volume":"88","author":"M Mannerstr\u00f6m","year":"2001","unstructured":"Mannerstr\u00f6m M, M\u00e4enp\u00e4\u00e4 H, Toimela T, Salminen L, T\u00e4hti H. The phagocytosis of rod outer segments is inhibited by selected drugs in retinal pigment epithelial cell cultures. Pharmacol Toxicol. 2001;88:27\u201333.","journal-title":"Pharmacol Toxicol"},{"key":"1280_CR15","doi-asserted-by":"publisher","first-page":"4747","DOI":"10.1167\/iovs.13-13662","volume":"55","author":"LA Kim","year":"2014","unstructured":"Kim LA, Amarnani D, Gnanaguru G, Tseng WA, Vavvas DG, PA D\u2019A. Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms. Invest Ophthalmol Vis Sci. 2014;55:4747\u201358.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1280_CR16","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1073\/pnas.1717338115","volume":"115","author":"M Hata","year":"2018","unstructured":"Hata M, Ikeda HO, Iwai S, Iida Y, Gotoh N, Asaka I, et al. Reduction of lipid accumulation rescues Bietti's crystalline dystrophy phenotypes. Proc Natl Acad Sci U S A. 2018;115:3936\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1280_CR17","doi-asserted-by":"publisher","first-page":"126747","DOI":"10.1172\/jci.insight.126747","volume":"5","author":"E Ivanova","year":"2019","unstructured":"Ivanova E, Alam NM, Prusky GT, Sagdullaev BT. Blood-retina barrier failure and vision loss in neuron-specific degeneration. JCI Insight. 2019;5:126747.","journal-title":"JCI Insight"},{"key":"1280_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/ICB.0000000000000093","volume":"9","author":"KW Jeng","year":"2015","unstructured":"Jeng KW, Wheatley HM. Intravitreal triamcinolone acetonide treatment of tamoxifen maculopathy with associated cystoid macular edema. Ret Cases Brief Rep. 2015;9:64\u20136.","journal-title":"Ret Cases Brief Rep"},{"key":"1280_CR19","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1002\/glia.22666","volume":"62","author":"W Shen","year":"2014","unstructured":"Shen W, Lee SR, Araujo J, Chung SH, Zhu L, Gillies MC. Effect of glucocorticoids on neuronal and vascular pathology in a transgenic model of selective M\u00fcller cell ablation. Glia. 2014;62:1110\u201324.","journal-title":"Glia"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1280-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1280-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1280-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T00:29:56Z","timestamp":1609201796000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1280-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1280"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1280-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"26 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed consent was obtained after an explanation of the nature and possible consequences of the study, which followed the tenets outlined in the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}